RECRUITINGINTERVENTIONAL
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
About This Trial
Iatrogenic hypoglycemia is still considered to be the number one barrier to effective glycemic control in patients with type 1 diabetes (T1D). In a previous study, it was observed in people without diabetes that fasting can be detrimental to the hormonal and hepatic responses to insulin-induced hypoglycemia. In the experiments described herein, the impact fasting has on hypoglycemic counterregulation in people with T1D will be determined.
Who May Be Eligible (Plain English)
Who May Qualify:
- males and females of any race or ethnicity
- non-obese (BMI \< or = to 30)
- have a diagnosis of type 1 diabetes
- C-peptide negative
Who Should NOT Join This Trial:
- pregnant women
- cigarette smoking
- Taking inflammation-targeting steroids (e.g., prednisone).
- Taking medications targeting adrenergic signaling (e.g., beta-blockers, bronchodilators).
- Hematocrit less than 33%.
- Presence of HIV or hepatitis (due to their deleterious effects on the liver).
- The presence of cardiovascular or peripheral vascular disease.
- The presence of neuropathy, retinopathy or nephropathy.
- A detection of the presence of any other disease or condition by one of the study doctors, that would be expected to confound the responses to insulin-induced hypoglycemia or make participation in the study dangerous to the individual.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* males and females of any race or ethnicity
* non-obese (BMI \< or = to 30)
* have a diagnosis of type 1 diabetes
* C-peptide negative
Exclusion Criteria:
* pregnant women
* cigarette smoking
* Taking inflammation-targeting steroids (e.g., prednisone).
* Taking medications targeting adrenergic signaling (e.g., beta-blockers, bronchodilators).
* Hematocrit less than 33%.
* Presence of HIV or hepatitis (due to their deleterious effects on the liver).
* The presence of cardiovascular or peripheral vascular disease.
* The presence of neuropathy, retinopathy or nephropathy.
* A detection of the presence of any other disease or condition by one of the study doctors, that would be expected to confound the responses to insulin-induced hypoglycemia or make participation in the study dangerous to the individual.
Treatments Being Tested
OTHER
Fasting
Subjects remain fasted prior to insulin-induced hypoglycemia.
OTHER
Feeding
Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
Locations (1)
University of Cincinnati
Cincinnati, Ohio, United States